—
Type 2 Diabetes mellitus (T2DM) is a disease marked by lack of insulin, insulin resistance, and high blood sugar. This disease has long-term damage that results in failure and dysfunction of multiple organs including blood vessels, heart, nerves, kidneys, and eyes. About 85% of diabetics have the chances of getting T2DM. The rising cases of diabetes can be attributed to reduced physical activity and consumption of high-calorie diets. A healthy diet and lifestyle change can improve the chances of recovering from T2DM.The T2DM therapeutics market in Asia Pacific has evolved in the last decade. It has brought about promising treatments such as SGLT-2 inhibitor, GLP-1 receptor agonist, DPP-4 inhibitor, sulfonylureas, biguanide, and other insulin therapies. But alternative products offering better glycemic control hamper market growth. GIP (Gastric inhibitory polypeptide) is impaired during type 2 diabetes, but GLP-1 is preserved proving beneficial to therapy.
Browse Full Research Report With TOC On "Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth " at: http://www.radiantinsights.com/research/type-2-diabetes-mellitus-therapeutics-in-asia-pacific-markets
Sulfonylureas help your body secrete more insulin. Examples of medication in this class of medicines are glipizide and glyburide. Meglitinides work similarly to sulfonylureas but are faster-acting agents. Examples of medication include nateglinide and repaglinide. DPP-4 inhibitors reduce blood sugar levels and negate the possibility of weight gain. Examples include saxagliptin and sitagliptin.
Bariatric surgery is an option for obese patients suffering from T2DM. The T2DM therapeutics market in Asia Pacific is projected to reach about 10.2 billion by 2021, growing at a 7.7% CAGR from 2014 to 2021. It was previously estimated to be worth USD 6 billion in 2013. With over 500 active drugs in the pipeline, many drug-testing candidates are evaluated and given advanced drugs and insulin therapies. In an analysis of clinical trials, T2DM molecules had a failure rate of over 50% in Phase II, with an attrition rate of 86%.
Browse All Reports of This Category at:
• Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 –
http://www.radiantinsights.com/research/cystic-fibrosis-therapeutics-in-major-developed-markets-to-2019-cftr-modulators-initiate-drive-towards-personalized-treatment-and-market-growth
• Glucose Monitoring Device Market to 2019 –
http://www.radiantinsights.com/research/glucose-monitoring-device-market-to-2019-technology-adoption-and-increasing-health-awareness-serve-as-distinct-regional-growth-drivers
About Radiant Insight
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets.
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights Inc.
United States
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Web: http://www.radiantinsights.com
Contact Info:
Name: Michelle Thoras
Email: Send Email
Organization: Radiant Insights, Inc.
Address: 28 2nd Street
Phone: 14153490054
Website: http://www.radiantinsights.com/research/type-2-diabetes-mellitus-therapeutics-in-asia-pacific-markets
Release ID: 104507